• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫介导毒性的管理及其对晚期肾癌结局的影响

Management of immune-mediated toxicities and their implications in the outcomes of advanced kidney cancer.

作者信息

Roy Arya Mariam, George Saby

机构信息

Department of Medical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

出版信息

Immunotherapy. 2023 Apr;15(6):397-400. doi: 10.2217/imt-2023-0010. Epub 2023 Mar 2.

DOI:10.2217/imt-2023-0010
PMID:36861344
Abstract

Plain language summary Targeted immunotherapy refers to a new class of drugs that boost the body's immune system to fight against cancer. Studies have shown that immunotherapy increases the survival of kidney cancer patients, but it has certain side effects that can affect any organ in the body, including the heart, lungs, skin, bowel and thyroid. Most side effects can be managed with drugs that can suppress the immune system, such as steroids; however, some side effects can be fatal if not diagnosed in a timely manner. It is vital to have a proper understanding of the side effects of immunotherapy drugs when making decisions about treatment for kidney cancer.

摘要

通俗易懂的总结 靶向免疫疗法是指一类新型药物,可增强人体免疫系统以对抗癌症。研究表明,免疫疗法可提高肾癌患者的生存率,但它有某些副作用,可能会影响身体的任何器官,包括心脏、肺、皮肤、肠道和甲状腺。大多数副作用可用抑制免疫系统的药物(如类固醇)来控制;然而,有些副作用如果不及时诊断可能会致命。在决定肾癌治疗方案时,正确了解免疫疗法药物的副作用至关重要。

相似文献

1
Management of immune-mediated toxicities and their implications in the outcomes of advanced kidney cancer.免疫介导毒性的管理及其对晚期肾癌结局的影响
Immunotherapy. 2023 Apr;15(6):397-400. doi: 10.2217/imt-2023-0010. Epub 2023 Mar 2.
2
The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.与免疫检查点抑制剂相关的极重度免疫相关不良事件的决定因素:法国 REISAMIC 注册前瞻性研究。
Eur J Cancer. 2021 Nov;158:217-224. doi: 10.1016/j.ejca.2021.08.048. Epub 2021 Oct 7.
3
New insight in endocrine-related adverse events associated to immune checkpoint blockade.免疫检查点阻断相关内分泌不良事件的新认识。
Best Pract Res Clin Endocrinol Metab. 2020 Jan;34(1):101370. doi: 10.1016/j.beem.2019.101370. Epub 2019 Dec 11.
4
[Therapy monitoring and management of adverse events in PD-1/PD-L1 immune checkpoint inhibition].[PD-1/PD-L1免疫检查点抑制治疗中的不良事件监测与管理]
Urologe A. 2016 May;55(5):677-90. doi: 10.1007/s00120-016-0109-2.
5
Supportive care for patients undergoing immunotherapy.免疫治疗患者的支持性护理。
Support Care Cancer. 2017 Oct;25(10):3017-3030. doi: 10.1007/s00520-017-3802-9. Epub 2017 Jul 13.
6
Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.免疫检查点抑制剂治疗晚期肾细胞癌:现有经验与未来方向。
Ann Oncol. 2017 Jul 1;28(7):1484-1494. doi: 10.1093/annonc/mdx151.
7
Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer.癌症免疫治疗不良事件的新兴管理方法。
Molecules. 2022 Jun 13;27(12):3798. doi: 10.3390/molecules27123798.
8
Rare and Insidious Toxicities from New Combination Therapies in Metastatic Renal Cell Cancer: Lessons Learned from Real-Practice.转移性肾细胞癌新型联合治疗方案的罕见且隐匿性毒性:真实实践中汲取的经验教训。
Curr Oncol. 2022 Sep 22;29(10):6776-6786. doi: 10.3390/curroncol29100533.
9
Immunotherapy Toxicities.免疫疗法的毒性反应。
Surg Oncol Clin N Am. 2019 Jul;28(3):387-401. doi: 10.1016/j.soc.2019.02.009. Epub 2019 Apr 5.
10
Management of Immunotherapy Adverse Events in Oncological Patients: Anti-CTLA-4, Anti-PD-1/PD-L1.肿瘤患者免疫治疗不良事件的管理:抗CTLA-4、抗PD-1/PD-L1
Rev Recent Clin Trials. 2020;15(4):339-346. doi: 10.2174/1574887115666200622161418.

引用本文的文献

1
CTSS in the tumor microenvironment links immune escape and immunotherapy sensitivity in kidney renal clear cell carcinoma.肿瘤微环境中的CTSS与肾透明细胞癌的免疫逃逸和免疫治疗敏感性相关。
Discov Oncol. 2025 Jul 29;16(1):1439. doi: 10.1007/s12672-025-03267-8.
2
Emerging resistance losing response to immune check point inhibitors in renal cell carcinoma: two differing phenomena.肾细胞癌中出现的耐药性——对免疫检查点抑制剂失去反应:两种不同现象。
Cancer Drug Resist. 2023 Sep 20;6(3):642-655. doi: 10.20517/cdr.2023.47. eCollection 2023.